Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis.
Thirty-six patients with subarachnoid and intraventricular cysticercosis were randomly assigned to receive albendazole at 15 or 30 mg/kg/day plus dexamethasone for 8 days. Results favored a higher dose, with larger cyst reduction on MRI at 90 and 180 days and higher albendazole sulfoxide levels in plasma. An albendazole course at 30 mg/kg/day combined with corticosteroids is safe and more effective than the usual dose. A single treatment was insufficient in intraventricular and giant cysts.
Göngora-Rivera
F
F
Department of Neurology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
Soto-Hernández
J L
JL
González Esquivel
D
D
Cook
H J
HJ
Márquez-Caraveo
C
C
Hernández Dávila
R
R
Santos-Zambrano
J
J
D000328:Adult; D015766:Albendazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000923:Anticestodal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002552:Cerebral Ventricles / Q000469:parasitology*; D003907:Dexamethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D020019:Neurocysticercosis / Q000188:drug therapy*; D013346:Subarachnoid Space / Q000469:parasitology*; D016896:Treatment Outcome
D000923:Anticestodal Agents; D003907:Dexamethasone; D015766:Albendazole